Jeffrey Finer, CEO of Septerna, shares insights from their recent successful IPO. Troy Ignelzi, CFO of Rapport Therapeutics, discusses strategies that led to their upsized IPO. Chirag Surti from Morgan Stanley highlights market trends and investor engagement. The panel emphasizes the evolution of the biotech IPO landscape, focusing on strategic planning, disciplined valuation, and the importance of compelling narratives. They predict a hopeful outlook for 2025, with anticipated breakthroughs and a stronger emphasis on quality therapeutic areas in this revitalized market.
